Aberrant expression of microRNA-99a and its target gene mTOR associated with malignant progression and poor prognosis in patients with osteosarcoma

Jiali Zhao^{1,2,*}
 Fengli Chen^{3,*}
 Quan Zhou²
 Wei Pan²
 Xinhong Wang²
 Jin Xu²
 Li Ni¹
 Huilin Yang¹

¹Department of Orthopedics,
 The First Affiliated Hospital of
 Soochow University, Suzhou,

²Department of Orthopedics,
 The Affiliated Huai'an Hospital of
 Xuzhou Medical College and The
 Second People's Hospital of Huai'an,
 Huai'an, ³Central Laboratory, Huai'an
 First People's Hospital, Nanjing
 Medical University, Huai'an, Jiangsu,
 People's Republic of China

*These authors contributed equally
 to this work

Background: The mammalian target of rapamycin (mTOR) has been reported to act as a target gene of microRNA (miR)-99a in various cancer cells and identified as an independent prognostic marker of human osteosarcoma. The aim of this study was to investigate the clinical significance of miR-99a/*mTOR* axis in human osteosarcoma.

Methods: A total of 130 pairs of osteosarcoma and matched noncancerous bone tissues were used to detect the expression levels of miR-99a and *mTOR* mRNA by quantitative real-time polymerase chain reaction. Then, associations of miR-99a and/or *mTOR* expression with clinico-pathological features and prognosis of patients with osteosarcoma were statistically analyzed.

Results: The expression levels of miR-99a (tumor vs normal: 2.11 ± 1.03 vs 4.69 ± 1.21 , $P < 0.001$) and *mTOR* mRNA (tumor vs normal: 4.40 ± 1.13 vs 1.74 ± 0.85 , $P < 0.001$) in osteosarcoma tissues were, respectively, lower and higher than those in noncancerous bone tissues. The expression levels of miR-99a in osteosarcoma tissues were negatively correlated with those of *mTOR* mRNA. Additionally, miR-99a-low and/or *mTOR*-high expression were all significantly associated with advanced surgical stage, positive metastasis and recurrence, and poor response to chemotherapy (all $P < 0.05$). Moreover, patients with osteosarcoma with miR-99a-low and/or *mTOR*-high expression had shorter overall and disease-free survivals than those in miR-99a-high and/or *mTOR*-low expression groups. Multivariate Cox analyses showed that miR-99a and/or *mTOR* expression were all independent prognostic factors of osteosarcoma.

Conclusion: Our data showed the crucial role of miR-99a/*mTOR* axis in the malignant progression of human osteosarcoma, implying that conjoined expression of miR-99a and *mTOR* may offer an attractive novel prognostic marker for this disease.

Keywords: microRNA-99a, mammalian target of rapamycin, osteosarcoma, quantitative real-time PCR, prognosis

Introduction

Osteosarcoma, the most frequent primary malignant sarcoma of the bone in adolescents and young adults, derives from primitive bone-forming mesenchyme.¹ This disease has an estimated annual incidence rate of 4 million worldwide.² Despite great progress in therapeutic strategies, including surgery, adjuvant chemotherapy, radiotherapy, and biological therapy, the prognosis of patients with osteosarcoma remains unsatisfactory due to bone destruction, neoplastic bone formation, and pulmonary metastasis.³ Approximately 80% of patients with osteosarcoma eventually develop recurrent metastatic osteosarcoma following surgical operation, and the 3-year survival rate after pulmonary metastasectomy

Correspondence: Huilin Yang
 Department of Orthopedics, The First
 Affiliated Hospital of Soochow University,
 188 Shizi Street, Suzhou 215006, Jiangsu,
 People's Republic of China
 Tel/fax +86 512 6778 0101
 Email haeyspine@163.com

is ~30%.⁴ Several clinicopathological features, such as tumor size, response to chemotherapy, and metastasis status, have been used as prognostic indicators for patients with osteosarcoma, but they lack sensitivity and specificity. Similar to other malignancies, it is a multistep process with accumulation of complex molecular changes in the development and progression of osteosarcoma. However, the underlying molecular mechanism of this disease has not been fully elucidated.

MicroRNAs (miRs), a class of endogenous, noncoding, short (18–25 nucleotides in length), single-stranded RNA molecules, are regarded as negative regulators of gene expression at the posttranscriptional level through binding to the 3' untranslated region of target mRNAs, leading to translational inhibition and/or mRNA degradation.^{5,6} Growing evidence shows that miRs play crucial roles in various cellular processes, including development, cell growth, proliferation, differentiation, cell cycle, and apoptosis.⁷ In addition to the involvement in these biological processes, accumulating studies have reported that the dysregulation of miRs can contribute to a number of diseases, including cancer. Several miRs have been found to be upregulated or downregulated in several cancer tissues compared with the normal tissues of origin, implying that these miRs may function as either oncogenes or tumor suppressors with a cancer-specific manner.^{8,9} miR-99a, together with miR-100, belongs to the miR-99 family, which has been reported to be implicated into carcinogenesis and cancer progression of various human malignancies. miR-99a, located in intron 13 of the *C21orf34* gene at chromosome 21q,¹⁰ has been observed to be deregulated in head and neck squamous cell carcinoma,¹¹ squamous cell lung carcinoma,^{12–14} hepatocellular carcinoma,¹⁵ ovarian carcinoma,¹⁶ bladder cancer,^{17,18} and prostate cancer¹⁹ and has been reported to exert an antitumor activity in these malignancies.

Mammalian target of rapamycin (mTOR), an evolutionarily conserved serine/threonine protein kinase, belongs to the phosphoinositide-3-kinase (PI3 K)-related kinase family.²⁰ mTOR mainly controls protein synthesis via phosphorylation of its downstream targets and interacts with several proteins to form two distinct complexes: mTOR complex 1 and 2.²¹ Recent studies have indicated that the dysregulation of the mTOR signaling pathway may be involved in various human cancers with gain- or loss-of-function mutants leading to neoplastic transformation.^{22–30} Our research group previously found that the aberrant expression of mTOR might be an independent prognostic marker of human osteosarcoma.³¹ Although *mTOR* has been reported to be a target gene of miR-99a,^{32–34} the involvement of miR-99a in human

osteosarcoma remains unclear. Thus, the aim of this study was to investigate the clinical significance of miR-99a/mTOR axis in this disease.

Materials and methods

Patients and tissue samples

The collection and the use of all tissue samples in the present study were approved by the Research Ethics Committee of The Affiliated Huai'an Hospital of Xuzhou Medical College, People's Republic of China (No HA20130068). Written informed consent was obtained from all the patients. All specimens were handled and made anonymous according to the ethical and legal standards.

A total of 130 tumor tissues and self-matched noncancerous bone tissues collected from 130 patients with osteosarcoma were retrospectively enrolled according to the surgical pathology records of The Affiliated Huai'an Hospital of Xuzhou Medical College, from 2000 to 2008. The patients received X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy for the diagnosis. All the tumors were confirmed pathologically from the specimens obtained from surgery. All the tissues analyzed were obtained after treatment with neoadjuvant chemotherapy. All patients received the uniform preoperative multiagent chemotherapy following the initial biopsy. The cytotoxic drugs used as preoperative chemotherapy were *cis*-diamminedichloroplatinum, adriamycin, vincristine, ifosfamide, and high-dose methotrexate. The resected specimens were analyzed histologically for response to chemotherapy according to the criteria released previously; the corresponding clinical information was obtained from medical records.³⁵ The clinical and pathologic parameters were obtained from the pathological reports and presented in Table 1.

All 130 patients with osteosarcomas underwent follow-up from 3 months to 102 months (median, 48 months). The follow-up was ended on June 30, 2013. Patients were monitored with CT performed every 3 months during the first 3 years after chemotherapy, every 4 months during years 4 and 5, and every 6 months thereafter. The development of local recurrence and distant metastases was detected by CT scans or MRI. All cases were independently reviewed by two pathologists and discrepancies resolved by consensus review. Of 130 patients with osteosarcomas, 88 (67.69%) patients were alive and 42 (32.31%) patients had died of the disease. Overall survival time was calculated from the date of the initial surgical operation to death. Disease-free survival was calculated from the date of the initial surgical

Table I Associations of miR-99a and/or *mTOR* mRNA expressions with the clinicopathological characteristics of primary osteosarcoma

Clinicopathological characteristics	No of patients (n, %)	miR-99a-low (%)	P-value	mTOR-high (%)	P-value	miR-99a-low/ mTOR-high (%)	P-value
Age (years)							
<20	58 (44.62)	30 (51.72)	NS	30 (51.72)	NS	20 (34.48)	NS
≥20	72 (55.38)	40 (55.56)		38 (52.78)		28 (38.89)	
Sex							
Male	92 (70.77)	50 (54.35)	NS	47 (51.09)	NS	32 (34.78)	NS
Female	38 (29.23)	20 (52.63)		21 (55.26)		16 (42.11)	
Tumor size							
≤5 cm	60 (46.15)	32 (53.33)	NS	30 (50.00)	NS	20 (33.33)	NS
>5 cm	70 (53.85)	38 (54.29)		38 (54.29)		28 (40.00)	
Tumor location							
Femur	60 (46.15)	32 (53.33)	NS	32 (53.33)	NS	23 (38.33)	NS
Tibia	40 (30.77)	22 (55.00)		20 (50.00)		15 (37.50)	
Humerus	24 (18.45)	13 (54.17)		13 (54.17)		8 (33.33)	
Fibula	6 (4.62)	3 (50.00)		3 (50.00)		2 (33.33)	
Surgical stage							
IIA	55 (42.31)	20 (36.36)	0.01	20 (36.36)	0.01	10 (18.18)	0.008
IIB/III	75 (57.69)	50 (66.67)		48 (64.00)		38 (50.67)	
Metastasis							
No	73 (56.15)	21 (28.77)	0.006	18 (24.66)	0.005	6 (8.22)	0.002
Yes	57 (43.85)	49 (85.96)		50 (87.72)		42 (73.68)	
Recurrence							
No	76 (58.46)	25 (32.89)	0.01	22 (28.95)	0.006	8 (10.53)	0.002
Yes	54 (41.54)	45 (83.33)		46 (85.19)		40 (74.07)	
Histological subtype							
Osteoblastic	70 (53.85)	35 (50.00)	NS	35 (50.00)	NS	25 (35.71)	NS
Chondroblastic	28 (21.54)	16 (57.14)		16 (57.14)		10 (35.71)	
Fibroblastic	21 (16.15)	12 (57.14)		11 (52.38)		7 (33.33)	
Mixed type	6 (4.62)	4 (66.67)		3 (50.00)		3 (50.00)	
Small type	5 (3.85)	3 (60.00)		3 (60.00)		3 (60.00)	
Response to chemotherapy							
Good	75 (53.85)	30 (40.00)	0.02	28 (37.33)	0.02	10 (13.33)	0.01
Poor	55 (46.15)	40 (72.73)		40 (72.73)		38 (69.09)	

Abbreviations: miR, microRNA; NS, not significant.

operation to the date of second cancer, tumor recurrence, distant metastases, or death from any cause.

Quantitative real-time polymerase chain reaction

The expression levels of miR-99a and *mTOR* mRNA in 130 pairs of osteosarcoma and matched noncancerous bone tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA in fresh tissues was extracted by using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) based on the manufacturer's instructions. For the detection of miR-99a and RNU6B used as internal controls, TaqMan MicroRNA Assays (Thermo Fisher Scientific) with primers specific to miR-99a and RNU6B were used. Reverse transcription was performed using One Step PrimeScript

miRNA cDNA Synthesis Kit (Thermo Fisher Scientific), and qRT-PCR was performed using SYBR Premix Ex TaqII (Thermo Fisher Scientific). qRT-PCR primer sequences were as follows: miR-99a, forward 5'-GGA ACC CGT AGA TCC GAT-3' and reverse 5'-GTG CAG GGT CCG AGG T-3'; RNU6B, forward 5'-ACA GUA GUC UGC ACA UUG GUU A-3' and reverse 5'-ACG CAA ATT CGT GAA GCG TT-3'. For the detection of *mTOR* mRNA and β -actin mRNA used as internal controls, reverse transcription was performed using PrimeScript RT Master Mix (Thermo Fisher Scientific), and qRT-PCR was carried out using SYBR Premix Ex Taq II (Thermo Fisher Scientific). qRT-PCR primer sequences were as follows: *mTOR*, forward 5'-AGA TTT AAT GGA GGC CCA GG-3' and reverse 5'-GGC CTC TGT TTG GAT GTG AT-3'; β -actin, forward 5'-GGT CAG AAG

GAC TCC TAT GTG G-3' and reverse 5'-TGT CGT CCC AGT TGG TAA CA-3'. qRT-PCR was performed using an ABI 7500 Real-Time PCR Detection System (Thermo Fisher Scientific). The threshold cycle (C_t) was defined as the fractional cycle number at which the fluorescence passed the fixed threshold. Each sample was detected three times, and the relative expression level of miR-99a/*mTOR* to RNU6/ β -actin was calculated using the $2^{-\Delta C_t}$ method, where $\Delta C_t = (C_{t \text{ miR-99a/mTOR}} - C_{t \text{ RNU6/\beta-actin}})$. The median values of miR-99a and *mTOR* mRNA expression levels in osteosarcoma tissues were used as cutoff points for dividing miR-99a-low/high groups and *mTOR*-low/high groups, respectively.

Statistical analysis

SPSS software for Windows (version 13.0; SPSS Inc., Chicago, IL, USA) was used to perform statistical analyses in this study. Fisher's exact test was used for any 2×2 tables, Pearson χ^2 test for non-2×2 tables, chi-square trend test for ordinal datum, and Kaplan–Meier and Cox regression methods for the question of survival analysis. Spearman's rank correlation is used to analyze the correlation between the expression of miR-99a and *mTOR* mRNA. Differences were considered statistically significant when P - was <0.05.

Results

Dysregulation of miR-99a/*mTOR* axis in human osteosarcoma tissues

The expression levels of miR-99a (tumor vs normal: 2.11 ± 1.03 vs 4.69 ± 1.21 , $P < 0.001$; Figure 1A) and *mTOR* mRNA (tumor vs normal: 4.40 ± 1.13 vs 1.74 ± 0.85 , $P < 0.001$; Figure 1A) in osteosarcoma tissues were, respectively, lower and higher

than those in noncancerous bone tissues. Of 130 patients with osteosarcoma, 70 (53.85%) and 68 (52.31%) had low miR-99a expression and high *mTOR* mRNA expression, respectively; 20 (15.38%) had both high expression of miR-99a and *mTOR*; 22 (16.92%) had both low expression of miR-99a and *mTOR*; 40 (30.77%) had miR-99a-high and *mTOR*-low expression; and 48 (36.92%) had miR-99a-low and *mTOR*-high expression. The expression levels of miR-99a in osteosarcoma tissues were negatively correlated with those of *mTOR* mRNA ($r = -0.36$, $P = 0.02$; Figure 1B).

Dysregulation of miR-99a/*mTOR* axis associates with malignant progression of human osteosarcoma

Table 1 summarized the associations of miR-99a and/or *mTOR* mRNA expression with the clinicopathological characteristics of patients with osteosarcoma. The statistical analyses revealed that miR-99a-low and/or *mTOR*-high expression were all significantly associated with advanced surgical stage, positive metastasis and recurrence, and poor response to chemotherapy (all $P < 0.05$). There was no significant associations with age, sex, tumor size, tumor location, or histological subtype (all $P > 0.05$; Table 1).

Dysregulation of miR-99a/*mTOR* axis predicts poor prognosis in human osteosarcoma

Associations of miR-99a and/or *mTOR* expression in osteosarcoma tissues with patients' prognosis were further evaluated by Kaplan–Meier analysis and log-rank test. As shown in Figure 2, patients with osteosarcoma with low miR-99a

Figure 1 Dysregulation of miR-99a/*mTOR* axis in human osteosarcoma tissues.

Notes: (A) miR-99a (tumor vs normal: 2.11 ± 1.03 vs 4.69 ± 1.21 , $P < 0.001$) and *mTOR* mRNA (tumor vs normal: 4.40 ± 1.13 vs 1.74 ± 0.85 , $P < 0.001$) expression levels in osteosarcoma tissues were, respectively, lower and higher than those in noncancerous bone tissues. (B) Expression levels of miR-99a in osteosarcoma tissues were negatively correlated with those of *mTOR* mRNA ($r = -0.36$, $P = 0.02$).

Abbreviation: miR, microRNA.

expression and high *mTOR* expression had both shorter disease-free survival (Figure 2A and C, respectively, both $P<0.001$) and shorter overall survival (Figure 2B and D, respectively, both $P<0.001$) than those with high miR-99a expression and low *mTOR* expression. The association between the combined expression of miR-99a/*mTOR* and the survival rates was also tested by Kaplan–Meier analysis. The results by pairwise comparisons showed that miR-99a-low/*mTOR*-high subjects had the poorest prognosis in miR-99a-low (high)/*mTOR*-high (low) groups ($P<0.001$; Figure 2E and F).

Moreover, univariate analysis showed that the advanced surgical stage, positive recurrence and metastasis, miR-99a low expression, *mTOR* mRNA high expression, the combined miR-99a-low/*mTOR*-high expression, and the poor

response to chemotherapy were all significantly correlated with poor overall survival ($P\leq 0.001$, $P\leq 0.006$, $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively; Table 2) and disease-free survival ($P\leq 0.001$, $P\leq 0.01$, $P<0.001$, $P<0.001$, $P<0.001$, and $P<0.001$, respectively; Table 2) of patients with osteosarcoma.

Furthermore, multivariate analysis as shown in Table 3 showed that the surgical stage (both $P=0.001$), the status of recurrence (both $P=0.022$) and metastasis ($P=0.009$ and $P=0.013$, respectively), miR-99a expression (both $P=0.01$), *mTOR* mRNA expression (both $P=0.01$), the combined miR-99a/*mTOR* expression (both $P=0.001$), and the response to chemotherapy ($P=0.011$ and $P=0.016$, respectively) were all independent prognostic factors for overall and disease-free survivals.

Figure 2 (Continued)

Figure 2 Associations of miR-99a expression (**A** and **B**), mTOR expression (**C** and **D**) and the co-expression of miR-99a/mTOR (**E**) and (**F**) with disease-free and overall survivals of patients with primary osteosarcoma.

Abbreviation: miR, microRNA.

Discussion

Screening novel markers for human osteosarcoma may be essential for the accurate identification of the biological features of tumors, the improvement of targeted therapies, and the prediction of patients' outcome. Growing evidence

shows that the dysregulation of miR–target mRNA axis can contribute to tumorigenesis, tumor progression, and prognosis. In the current study, we demonstrated that miR-99a and its target gene *mTOR* were, respectively, expressed at low and high levels in clinical osteosarcoma tissues.

Table 2 Univariate analysis of prognostic parameters in patients with osteosarcomas by Cox regression analysis

Variables	Overall survival		Disease-free survival	
	P-value	RR	P-value	RR
Age at diagnosis (years)				
<20 vs ≥ 20	0.125	0.691	0.118	0.651
Sex				
Male vs female	0.112	0.916	0.110	0.846
Tumor size (cm)				
<5.0 vs ≥ 5.0	0.312	0.568	0.310	0.521
Tumor location				
Femur vs tibia and others	0.200	0.899	0.213	0.887
Surgical stage				
IIA vs IIB/III	<0.001	8.782	<0.001	8.312
Histological subtype				
Osteoblastic vs others	0.116	0.925	0.119	0.921
Recurrence				
No vs yes	0.006	4.732	0.01	4.098
Metastasis				
No vs yes	<0.001	8.279	<0.001	8.132
Response to chemotherapy				
Good vs poor	<0.001	8.026	<0.001	7.969
miR-99a expression				
Low vs high	<0.001	8.822	<0.001	8.066
mTOR expression				
Low vs high	<0.001	7.813	<0.001	7.268
miR-99a/mTOR expression				
miR-99a-low/mTOR-high vs others	<0.001	8.826	<0.001	8.292

Abbreviations: miR, microRNA; RR, relative risk.

Table 3 Multivariate analysis of prognostic parameters in patients with osteosarcomas by Cox regression analysis

Prognostic factors	Overall survival		Disease-free survival	
	Relative risk (95% confidence interval)	P-value	Relative risk (95% confidence interval)	P-value
Recurrence	2.167 (0.980–4.561)	0.022	2.020 (0.972–4.416)	0.022
Surgical stage	6.668 (1.310–14.968)	0.001	6.392 (1.286–14.129)	0.001
Metastasis	5.020 (1.051–11.109)	0.009	5.006 (1.109–11.088)	0.013
Response to chemotherapy	3.252 (0.932–7.867)	0.01	3.158 (0.973–7.567)	0.01
miR-99a expression	5.232 (1.022–12.398)	0.01	5.176 (1.003–11.928)	0.01
mTOR expression	5.312 (1.021–12.299)	0.01	5.229 (1.033–12.018)	0.01
miR-99a/mTOR expression	6.891 (1.398–15.296)	0.001	6.693 (1.312–14.895)	0.001

Abbreviation: miR, microRNA.

The downregulation of miR-99a expression and the upregulation of *mTOR* mRNA, alone or in combination, were all significantly correlated with the recurrence, the metastasis, and the response to chemotherapy of patients with osteosarcoma. Using multivariate Cox regression analysis, the aberrant expression of miR-99a and/or *mTOR* mRNA was shown to be independent predictors for worse prognosis in patients with osteosarcoma. To the best of our knowledge, this is the first time to determine the expression patterns and clinical significance of miR-99a/*mTOR* axis in the progression and prognosis of human osteosarcoma.

miR-99a has been reported to be frequently lost or expressed at a reduced level and to function as a tumor suppressor in various human cancers. For example, Wu et al¹⁷ found that miR-99a inhibited cell proliferation, migration, and invasion in bladder cancer cell lines by directly targeting fibroblast growth factor receptor 3. Yu et al¹² reported that miR-99a was downregulated in non-small-cell lung cancer tissues, which was significantly associated with last-stage and tumor metastasis in patients with this malignancy. Further functional experiments also found that the overexpression of miR-99a could inhibit cell proliferation, migration, and invasion of non-small-cell lung cancer cells in vitro and tumor metastasis of non-small-cell lung cancer in vivo. Wang et al³⁶ indicated that the reduced miR-99a expression was highly associated with lymph node metastasis and shorter overall survival of patients with breast cancer. Gain- and loss-of-function studies of this research group revealed that miR-99a efficiently inhibited breast cancer cell proliferation, migration, and invasion. Li et al¹⁵ showed that miR-99a expression was correlated with the survival of patients with hepatocellular carcinoma, and the restoration of this miR suppressed the growth of hepatocellular carcinoma cells in vitro and in vivo by targeting insulin-like growth factor 1 receptor and *mTOR*. Cui et al³⁷ found that miR-99a was remarkably downregulated in renal cell carcinoma and low expression level of miR-99a was correlated

with poor survival of patients with renal cell carcinoma. Further functional experiments of these authors validated the inhibitory effects of miR-99a on the growth of cancer cells, clonability, migration, and invasion as well as induced G1-phase cell cycle arrest in vitro, and the tumor growth in murine xenograft models. Jiang et al¹⁶ also observed that the overexpression of miR-99a could significantly inhibit epithelial ovarian cancer cell proliferation in vitro by decreasing the expression of FGFR3. Although these previous findings suggest the important roles of miR-99a in the suppression of tumor aggressive progression and malignant phenotypes of multiple cancer types, its definite function of human osteosarcoma has not been described yet.

Recent functional analyses have shown the regulatory effect of miR-99a on *mTOR* and identified *mTOR* as a direct target of miR-99a.^{24–26} For example, Gu et al³⁸ found that the transfection of miR-99a mimics could induce the decreased expression of mTOR protein in human lung adenocarcinoma cells, while transfection of miR-99a inhibitor could induce the increased expression of mTOR protein, implying that *mTOR* was a direct target of miR-99a in lung adenocarcinoma cells. Yang et al²⁴ performed the qRT-PCR, and Western blot assays indicated that the overexpression of miR-99a could suppress the expression of *mTOR* in breast cancer cells. Huang et al¹⁰ also confirmed the regulatory effects of miR-99a on *mTOR* in human anaplastic thyroid cancer by luciferase assay. Our research group performed the immunohistochemistry and confirmed the overexpression of mTOR protein in osteosarcoma tissues. We also found the significant associations between mTOR overexpression and tumor progression and prognosis in patients with osteosarcoma.²³ These previous findings prompted us to investigate the clinical significance of miR-99a/*mTOR* interaction in this malignancy. Here, our results showed that miR-99a was decreased, while *mTOR* mRNA was increased in osteosarcoma tissues. We also proved that the relative expression levels of miR-99a and *mTOR* mRNA, alone or in combination, were also associated

with advanced clinicopathological characteristics of patients with osteosarcoma. Moreover, miR-99a low and *mTOR* mRNA high expressions were both correlated with shorter overall and disease-free survivals and could be independent prognostic factors in patients with osteosarcoma.

More interestingly, we also found that the patients with osteosarcoma with miR-99a-high/*mTOR*-low expression, among four different statuses of miR-99a/*mTOR* co-expression, had the best outcome, while the miR-99a-low/*mTOR*-high had the worst. Multivariate analysis revealed that the miR-99a-low/*mTOR*-high co-expression may be an independent prognostic indicator for osteosarcoma. The advantages of miR-99a/*mTOR* co-expression to individual miR-99a or *mTOR* in predicting the outcome of osteosarcoma have been shown in our result.

Conclusion

In conclusion, our data reveal the crucial role of miR-99a/*mTOR* axis in the malignant progression of human osteosarcoma, implying that conjoined expression of miR-99a and *mTOR* may offer an attractive novel prognostic marker for this disease.

Acknowledgments

This research was supported by grants from Jiangsu Provincial Special Program of Medical Science (No BL2012004), Jiangsu Provincial Clinical Orthopedic Center, and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Huai'an Technology Support Program (social development) funded projects (No HAS2015009-4).

Author contributions

All the authors participated in the design, interpretation of the studies, and analysis of the data and critically revised the manuscript. JZ, FC, QZ, and WP conducted the experiments; XW and JZ collected clinical samples; JZ and FC wrote the manuscript; and LN performed data analysis.

Disclosure

The authors report no conflicts of interest in this work.

References

- Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. *Nat Rev Cancer*. 2014;14:722–735.
- Moore DD, Luu HH. Osteosarcoma. *Cancer Treat Res*. 2014;162:65–92.
- Zhou W, Hao M, Du X, Chen K, Wang G, Yang J. Advances in targeted therapy for osteosarcoma. *Discov Med*. 2014;17:301–307.
- Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. *Curr Opin Pharmacol*. 2014;16:15–23.
- Iadevaia V, Gerber AP. Combinatorial control of mRNA fates by RNA-binding proteins and non-coding RNAs. *Biomolecules*. 2015;5:2207–2222.
- Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. *J Clin Med*. 2015;4:1651–1667.
- Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and potential targets in osteosarcoma: review. *Front Pediatr*. 2015;3:69.
- Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ. MicroRNAs in osteosarcoma. *Clin Chim Acta*. 2015;444:9–17.
- Orellana EA, Kasinski AL. MicroRNAs in cancer: a historical perspective on the path from discovery to therapy. *Cancers (Basel)*. 2015;7:1388–1405.
- Huang HG, Luo X, Wu S, Jian B. MiR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer. *Asian Pac J Cancer Prev*. 2015;16:4937–4944.
- Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. *Oral Oncol*. 2012;48:686–691.
- Yu SH, Zhang CL, Dong FS, Zhang YM. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. *J Cell Biochem*. 2015;116:268–276.
- Song Y, Dou H, Wang P, et al. A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling. *Cancer Biol Ther*. 2014;15:1423–1430.
- Chen C, Zhao Z, Liu Y, Mu D. microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. *Oncol Lett*. 2015;9:1128–1134.
- Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. *J Biol Chem*. 2011;286:36677–36685.
- Jiang H, Qu L, Wang Y, Cong J, Wang W, Yang X. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells. *Biomed Pharmacother*. 2014;68:163–169.
- Wu D, Zhou Y, Pan H, Zhou J, Fan Y, Qu P. microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. *Oncol Lett*. 2014;7:1219–1224.
- Feng Y, Kang Y, He Y, et al. microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. *BMC Urol*. 2014;14:50.
- Someya M, Yamamoto H, Nojima M, et al. Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer. *Radiother Oncol*. 2015;115:235–239.
- Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. *Am J Cancer Res*. 2015;5:1602–1609.
- Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. *Ann N Y Acad Sci*. 2015;1346:33–44.
- Gentilella A, Kozma SC, Thomas G. A liaison between mTOR signaling, ribosome biogenesis and cancer. *Biochim Biophys Acta*. 2015;1849:812–820.
- Cargnello M, Tcherkezian J, Roux PP. The expanding role of mTOR in cancer cell growth and proliferation. *Mutagenesis*. 2015;30:169–176.
- Yang J, Cheng D, Zhou S, Zhu B, Hu T, Yang Q. Overexpression of X-box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma. *Int J Mol Sci*. 2015;16:28635–28646.
- Horie R, Nakamura O, Yamagami Y, et al. Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells. *Int J Oncol*. 2016;48:37–44.
- Jiang H, Zeng Z. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma. *Biochem Biophys Res Commun*. 2015;468:255–261.
- Liu Y, Bi T, Dai W, et al. Lupeol induces apoptosis and cell cycle arrest of human osteosarcoma cells through PI3K/AKT/mTOR pathway. *Technol Cancer Res Treat*. Epub 2015 Oct 6.

28. Song R, Tian K, Wang W, Wang L. P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. *Int J Surg*. 2015;20:80–87.
29. Gupta A, Baker EK, Wan SS, et al. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. *Clin Cancer Res*. 2015;21:3216–3229.
30. Niu NK, Wang ZL, Pan ST, et al. Pro-apoptotic and pro-autophagic effects of the aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. *Drug Des Devel Ther*. 2015;9:1555–1584.
31. Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, Zhao J. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. *Med Oncol*. 2010;27:1239–1245.
32. Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. *PLoS One*. 2014;9:e92099.
33. Yang Z, Han Y, Cheng K, Zhang G, Wang X. miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. *Cell Prolif*. 2014;47:587–595.
34. Sun J, Chen Z, Tan X, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. *Med Oncol*. 2013;30:411.
35. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol*. 2002;20:776–790.
36. Wang X, Li Y, Qi W, et al. MicroRNA-99a inhibits tumor aggressive phenotypes through regulating HOXA1 in breast cancer cells. *Oncotarget*. 2015;6(32):32737–32747.
37. Cui L, Zhou H, Zhao H, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. *BMC Cancer*. 2012;12:546.
38. Gu W, Fang S, Gao L, Tan Y, Yang Z. Clinic significance of microRNA-99a expression in human lung adenocarcinoma. *J Surg Oncol*. 2013;108:248–255.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress